EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudieOpen Access · CC BY 4.0

Inter‐Laboratory Validation of Nodal/Paranodal Antibody Testing

Cinta Lleixà iD, Maarten Titulaer, Sophia Rohrbacher, Victor Mgbachi, Susan Halstead, Janev Fehmi, Elba Pascual-Goñi, Louisa Zhu, Luise Appeltshauser, Suzanne Franken, Manuela Paunovic, Patrick Waters und 6 weitere

Journal of the Peripheral Nervous System · 2025

DOI: 10.1111/jns.70000 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the Peripheral Nervous System, 2025. Verfasst von Cinta Lleixà und 17 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Hauptthemen laut MEDLINE: Autoantibodies, Autoimmune Diseases of the Nervous System. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Top Sector Life Sciences & Health (Health~Holland), Samenwerkende Gezondheidsfondsen (SGF), Erasmus MC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Reliable detection of antibodies against nodal targets is vital for the diagnosis of autoimmune nodopathies. The performance characteristics of recently developed in‐house assays are unknown. We compared testing at four centres.

Methods

Each submitted 29–40 serum samples to a coordinating centre from one of three groups: (1) autoimmune nodopathy patients, with positive nodal/paranodal antibodies; (2) seronegative patients with other inflammatory neuropathies, and (3) healthy individuals or those with other neurological diseases. The coordinating centre recoded all samples and returned 160 identical aliquots to each testing centre for blinded testing. Once data from all centres had been received by the coordinating centre, unblinded results were returned for analysis. Sensitivity was defined by the proportion of group 1 samples returned as positive. Accuracy was defined as 0.075(sensitivity) + 0.925(specificity).

Results

Centres performed various combinations of ELISA, cell‐based (CBAs) and teased‐nerve fibre assays. All labs produced highly accurate results (96%–100%) and concordance for the overall result across at least 3 or all 4 test centres was observed for 98% and 89% of the samples respectively. However, 10/30 individual assays (6/14 CBAs and 4/16 ELISAs) were less than 90% sensitive. Only 3 assays had more than 1 false positive result (2 ELISAs and 1 CBA). Combining different assay modalities to produce an overall result did not improve accuracy. Inter‐laboratory consistency in the determination of antibody subclasses was poor.

Interpretation

Although most samples were correctly categorised in all 4 centres, the use of a specific test modality or multiple tests did not guarantee accuracy. Early and repeated interlaboratory testing with sharing of samples is important to understand test performance and reproducibility, identify areas for improvement and maintain consistency. To aid this, we provide detailed methods for the best performing tests. Further standardisation of antibody subclass determination is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesAutoimmune Diseases of the Nervous SystemHumansEnzyme-Linked Immunosorbent AssayReproducibility of ResultsSensitivity and Specificity

Stichwörter der Autor:innen

CASPR1autoantibodiescontactin‐1immunoassayneurofascin

Substanzen

Autoantibodies

Autor:innen und Institutionen

  • Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Centro Para la Investigación en Red en Enfermedades Raras (CIBERER), Madrid, Spain.
  • Department of Neurology, Erasmus MC University Medical Center, Rotterdam, Netherlands.
  • Department of Neurology, University Hospital Würzburg, Würzburg, Germany.
  • Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • School of Infection and Immunity, University of Glasgow, Glasgow, UK.

ORCID-Profile: Cinta Lleixà, Hugh Willison, Ruth Huizinga, Kathrin Doppler

Förderung

  • Top Sector Life Sciences & Health (Health~Holland)
  • Samenwerkende Gezondheidsfondsen (SGF)
  • Erasmus MC
  • GBS-CIDP Foundation International
  • GBS|CIDP Foundation International
  • Interdisciplinary Center of Clinical Research (IZKF) of the Faculty of Medicine, University of Würzburg
  • Health~Holland
  • St.George Foundation

Zitieren

APA

Lleixà, C., Titulaer, M., Rohrbacher, S., Mgbachi, V., Halstead, S., Fehmi, J., Pascual-Goñi, E., Zhu, L., Appeltshauser, L., Franken, S., Paunovic, M., Waters, P., Willison, H., Sommer, C., Querol, L., Huizinga, R., Doppler, K., & Rinaldi, S. (2025). Inter‐Laboratory Validation of Nodal/Paranodal Antibody Testing. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.70000

Vancouver

Lleixà C, Titulaer M, Rohrbacher S, Mgbachi V, Halstead S, Fehmi J, et al. Inter‐Laboratory Validation of Nodal/Paranodal Antibody Testing. Journal of the Peripheral Nervous System. 2025. doi:10.1111/jns.70000

BibTeX
@article{Lleix2025,
  author = {Lleixà, Cinta and Titulaer, Maarten and Rohrbacher, Sophia and Mgbachi, Victor and Halstead, Susan and Fehmi, Janev and Pascual-Goñi, Elba and Zhu, Louisa and Appeltshauser, Luise and Franken, Suzanne and Paunovic, Manuela and Waters, Patrick and Willison, Hugh and Sommer, Claudia and Querol, Luis and Huizinga, Ruth and Doppler, Kathrin and Rinaldi, Simon},
  title = {Inter‐Laboratory Validation of Nodal/Paranodal Antibody Testing},
  journal = {Journal of the Peripheral Nervous System},
  year = {2025},
  doi = {10.1111/jns.70000}
}
Kostenlos starten →